Robert Wood Johnson Foundation

Menu
  • About RWJF
  • Our Work
  • Research & Publications
View All:
  • Grants
  • Topics
  • Blogs

Prescription Drugs and Services

You are now viewing 1 - 10 of 64 results

Sort results by:
  • Relevance
  • Alphabetical Order
  • Publication Date

Refine Your Results

  • Topic: Prescription drugs and services
  • Location: National
By Topic
  • Health policy (44)
  • Health care system (39)
  • Financial barriers to care (15)
  • Government, policy and legal issues (14)
  • Medicare (14)
  • Quality of care (13)
  • Public policy and regulation (11)
  • Patient-centered care/family-centered care (7)
  • Patient-provider collaboration (7)
  • Research (7)
  • State government (7)
  • Consumer engagement (7)
  • Health IT (6)
  • Information technology and tools (5)
  • Behavioral/mental health care (5)
By Content
  • Content Type
    • Journal Article (46)
    • Program Result (12)
    • Issue Brief (3)
    • Story (1)
    • Commentary (1)
    • Video (1)
  • Program Area
    • Human Capital (31)
    • Quality/Equality (13)
    • Coverage (12)
    • Pioneer (10)
    • Vulnerable Populations (3)
    • Enterprise Level (2)
    • Public Health (1)
By Demographics
  • Age
    • Seniors (65+) (4)
    • Adults (19-64 years) (2)
    • Children (6-10 years) (1)
    • Adolescents (11-18 years) (1)
  • Location
    • Urban (1)
  • States and Territories
    • District of Columbia (DC) SA (1)
    • New Mexico (NM) M (1)

Secondary Patenting of Branded Pharmaceuticals

October 10, 2012 | Journal Article

This article examines how secondary patents can extend market exclusivity and thus delay generic competition.

The Food and Drug Administration Has The Legal Basis to Restrict Promotion of Flawed Comparative Effectiveness Research

October 8, 2012 | Journal Article

Under FDA policy, communications by prescription drug manufacturers must be backed by “substantial evidence” from “adequate and well-controlled investigations.” But numerous exceptions permit manufacturer promotion based on data other than randomized trials.

User Fees and Beyond

October 4, 2012 | Journal Article

This perspective examines the Food and Drug Administration (FDA) Safety and Innovation Act (FDASIA) of 2012.

In Medicare Part D Plans, Low or Zero Copays and Other Features to Encourage the Use of Generic Statins Work, Could Save Billions

October 1, 2012 | Journal Article

This study examines how different drug plan benefit and formulary designs influence the selection of generic drugs to treat high cholesterol among Medicare beneficiaries.

Ethical Considerations in Orphan Drug Approval and Use

August 1, 2012 | Journal Article

While the 1983 Orphan Drug Act led to a boom in development and production of orphan drugs, inattentive regulatory standards may imperil patients with rare diseases.

Use of Prescription Drug Samples and Patient Assistance Programs, and the Role of Doctor¿Patient Communication

December 1, 2011 | Journal Article

Study found use of free drug samples widespread among older adults but participation in pharmaceutical industry-sponsored patient assistance programs very low.

An Empirical Review of Major Legislation Affecting Drug Development

September 1, 2011 | Journal Article

Using market exclusivity to promote pharmaceutical innovation can lead to positive outcomes, but the practice is also characterized by waste and collateral effects.

Designing Comparative Effectiveness Research on Prescription Drugs

October 1, 2010 | Journal Article

As comparative effectiveness research becomes a more prominent feature of clinical medicine, investigators and policy-makers would do well to seek lessons from prior examples of this type of research.

More Nonelderly Americans Face Problems Affording Prescription Drugs

January 1, 2009 | Issue Brief

More children and working-age Americans are going without prescription drugs because of cost concerns, according to a new national study by the Center for Studying Health System Change (HSC).

A Decade of Controversy

November 12, 2009 | Journal Article

Direct-to-consumer advertising (DTCA) of prescription drugs has remained controversial since regulations were liberalized by the FDA in 1997. This study reviewed empirical evidence addressing the claims made in the policy debate for and against DTCA.

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next
RWJF Home → Topics → Prescription Drugs and Services
  • Facebook
  • Twitter
  • YouTube
  • Email
  • RSS

Our mission: to improve the health and health care of all Americans.

  • About RWJF
    • Our Mission
    • Program Areas
    • From Our President
    • Leadership & Staff
    • Annual Reports
    • Newsroom
    • Job Opportunities
    • Office Location
    • Our Policies
  • Our Work
    • Health Policy
    • Prevention
    • Cost and Value
    • Leadership
    • All Topics
  • Program Areas
    • Childhood Obesity
    • Coverage
    • Human Capital
    • Pioneer
    • Public Health
    • Quality/Equality
    • Vulnerable Populations
  • Research & Publications
    • Find RWJF Research
    • Assessing Our Impact
    • How We Work
    • Data Center
    • RWJF DataHub
  • Grants
    • What We Fund
    • Calls for Proposals
    • Grantee Resources
    • FAQs
  • Blogs
    • Human Capital
    • New Public Health
    • Pioneering Ideas
  • My RWJF
    • Subscription Management
    • My Profile
  • Contact RWJF
  • Privacy Policy
  • Terms and Conditions

© 2001–2013 Robert Wood Johnson Foundation. All Rights Reserved.